FDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma

FDA Approves Tisagenlecleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma

header-info

The US Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.